Home-based transcutaneous electrical acupoint stimulation for high-normal blood pressure: A randomized controlled trial

Yu Wang MD\textsuperscript{1,2} | Jing-Wen Yang MD, PhD\textsuperscript{1,2} | Jun-Hong Liu MD, PhD\textsuperscript{3} | You-Sheng Qi MD, PhD\textsuperscript{3} | Jian-Feng Tu MD, PhD\textsuperscript{1,2} | Zhong-Xue Tian MM\textsuperscript{1,2} | Guang-Xia Shi MD, PhD\textsuperscript{1,2} | Shi-Yan Yan MD, PhD\textsuperscript{1,2} | Li-Qiong Wang MD, PhD\textsuperscript{1,2} | Cun-Zhi Liu MD, PhD\textsuperscript{1,2}

1\textsuperscript{1}International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China
2\textsuperscript{2}School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Chaoyang District, Beijing, China
3\textsuperscript{3}Heyi Community Health Service Center, Fengtai District, Beijing, China

Correspondence
Li-Qiong Wang, MD, PhD, International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No. 11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
Email: wangliqiongwork@163.com

The data underlying this article will be shared on reasonable request to the corresponding author.

The study was funded by the National Key R&D Program of China (2019YFC1712102) and the Fundamental Research Funds for the Central Universities (No. 2019-JYB-XJSJJ-31).

Financial disclosure: No financial disclosures were reported by the authors of this paper.
There was no racial or gender bias in the selection of participants.

Abstract
The authors investigated the effectiveness of home-based transcutaneous electrical acupoint stimulation (TEAS) combined with lifestyle modification on blood pressure (BP) control and explored the feasibility of the trial design in this prospective, randomized controlled trial. The authors recruited individuals with high-normal BP who had a systolic blood pressure (SBP) of 120–139 mm Hg and a diastolic blood pressure (DBP) of 80–89 mm Hg, or both. Participants were randomly assigned to receive either lifestyle modification combined with TEAS four times weekly for 12 weeks at home (intervention group) or solely lifestyle modification (control group). The primary outcome was the change in mean SBP at week 12 from the baseline measurement. A total of 60 participants were randomized in a 1:1 ratio, and an intention-to-treat analysis was performed on all of the outcomes. The mean difference in the change in SBP for the intervention group (compared to the control) at week 12 was $-3.85$ mm Hg (95\% CI: $-7.58$ to $-0.12$; $p = .043$); for the DBP, the change was $-2.27$ mm Hg (95\% CI: $-5.76$ to $1.23$; $p = .199$). There was no difference in the proportion of progression to hypertension, quality of life, body mass index (BMI) or waist circumference. In addition, two participants reported TEAS-related adverse events. The authors found a reduction in SBP control in the pragmatic, home-based intervention by using TEAS combined with lifestyle modification in adults with high-normal BP.

Trial Registration: The study was registered in the Chinese Clinical Trial Registry (ChiCTR 1900024982) on August 6, 2019.

KEYWORDS
acupuncture, high-normal blood pressure, lifestyle interventions, prehypertension, transcutaneous electrical acupoint stimulation
Elevated blood pressure (BP) is a leading preventable risk factor for many diseases and premature death throughout the world, and it causes a significant loss of quality of life.1–3 Adults with even a modest BP elevation (known as high-normal BP) have an increased risk of all-cause mortality.6,5 High-normal BP, which represents an earlier stage in the continuum of hypertension, affects 25%–50% of adults worldwide and increases the future risk of hypertension development.6 It also increases the risk of hypertension independently of other recognized risk factors7,8 and is closely associated with coronary heart disease, stroke and renal dysfunction.9

Prevention is considered the best strategy to lower the risk of high-normal BP progressing to hypertension and related damage to target organs.10 However, due to the low awareness rate and lack of appropriate therapies, a considerable number of individuals with high-normal BP have not been effectively controlled and have progressed to hypertension.6,11 It remains unclear whether to initiate treatment with a medication at the high-normal BP stage.12,13 For low-moderate risk individuals with high-normal BP, antihypertensive drug treatment currently lacks clinical trial evidence targeting prognostic endpoints.14 Lifestyle interventions are recommended as the first choice of therapy for reducing BP for high-normal BP patients without cardiovascular comorbidity in most clinical guidelines.6 Nevertheless, the challenges of lifestyle modifications extend beyond counseling for physicians and patient adherence.15 Most methods of lifestyle modifications require long-term persistence; otherwise, the modifications become ineffective, which is difficult for people who judge their health as being good. Hence, there is an urgent need to find new nonpharmaceutical therapy candidates to be developed into efficient and available therapies to address the growing burden of high-normal BP.

Transcutaneous electric acupoint stimulation (TEAS) is a novel therapy combining acupuncture and transcutaneous electric nerve stimulation techniques.16 It is considered a nonpharmaceutical, inexpensive and safe form of treatment that replaces acupuncture needles with surface electrodes. TEAS is widely used in gastrointestinal diseases and for perioperative and nonsurgical analgesia.17 It has been consistently shown to enhance vagal activity and inhibit sympathetic hyperexcitability,18–21 thereby potentially affecting BP. Previous studies using transcutaneous electrical stimulation have demonstrated a reduction in BP.22–26 This approach has the advantages of being easy to use, being more “user friendly,” requiring minimal training for physicians and patients and being convenient for clinical application at a health facility or at home.27 With the miniaturization of transcutaneous nerve stimulators, the use of TEAS treatment at home has become a clinical reality and would further reduce the time and transportation costs of travel to the hospital. Although TEAS has been shown to lower BP in several studies,22–25 few rigorous and long-term clinical trials addressing the intervention have been integrated within real-world practice settings to have sustainable, widespread applications among high-normal BP individuals. In this study, we investigated the effectiveness and safety of home-based TEAS combined with lifestyle modification in the treatment of high-normal BP and explored the feasibility of a trial design.

2 | METHODS

This study was a prospective, randomized and parallel design clinical trial conducted in China. The trial was conducted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines for the presentation of clinical trials28 and the principles of the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Beijing University of Chinese Medicine (2019BZHYLL0208). In addition, the study was registered in the Chinese Clinical Trial Registry (ChiCTR 1900024982) on August 6, 2019. Details of the trial’s design and analysis plan have been previously published.29

Participants were recruited at a large public-sector clinic in Beijing, China, from September 2019 to February 2020. They were screened for eligibility after written informed consent was obtained. Adults 35–65 years of age with a clinic-based systolic and/or diastolic BP of 120–139 mmHg and diastolic blood pressure (DBP) of 80–89 mmHg (from at least three separate visits) were enrolled. The individuals had to be able to completely answer the questionnaire and did not receive antihypertensive drugs or other drugs that affected BP over the previous 2 months. Pregnant women and people with contraindications for the use of electrostimulation, secondary hypertension, uncontrolled diabetes, drug abuse, alcohol abuse or participation in another research trial were excluded.

Eligible participants were randomly assigned (1:1) to the intervention group or the control group by using the block random method, and the block size was 6. The randomization sequence was prepared with SAS software (version 9.3, SAS Inc., Cary, NC, USA) by a professional statistician who was not involved in the assessment, treatment or analysis of the study to ensure the balance in baseline BP across the groups. Participants and study investigators who taught participants how to locate acupoints and use the TEAS instrument were not blinded. However, outcome assessors and statisticians were blinded to the group allocations. The automatic mode of the sphygmomanometer was used to measure BP without the need for intervention by the assessors, other than to place the cuff and to switch the device on.

2.1 | Intervention

Following randomization, all of the study participants received an assessment at baseline by trained study investigators. The assessment consisted of a series of questionnaires to evaluate sociodemographic characteristics, medical history, alcohol intake, smoking habits and quality of life.

All of the participants received advice for lifestyle modification from the study investigators. Information about weight control, increased physical activity, healthy eating, dietary sodium reduction, smoking abatement and limitation of alcohol consumption was sent to the
participants on a weekly basis via a social network app (WeChat, Tencent, Shenzhen, China). A previous study validated the use of the WeChat-based self-management intervention to control BP.30

The intervention group received the TEAS intervention, whereas the control group received no TEAS. The TEAS intervention was delivered via domestic equipment (SDP-330; Yuwell, Suzhou Medical Appliances Co., Ltd., Suzhou, China) by participants themselves in their home settings. The intervention lasted for 12 weeks, and follow-up lasted until 36 weeks after the initiation of treatment.

Before the start of the first treatment, a stimulator (with written instructions) and a participants’ manual were distributed to the participants, and they were taught how to properly perform the TEAS treatment at home. The study investigators instructed participants on how to locate the acupoints and to accurately use the stimulator. Pictures and videos of acupoints and operation demonstrations were distributed to help participants further familiarize themselves with the TEAS. The transcutaneous nerve stimulator has two 100-Hz output channels, and the intensity of the stimulation can be adjusted. The suitable intensity should be gradually increased to trigger the maximum sensory threshold without discomfort or pain. The self-adhesive electrodes were placed on the skin surface of the following bilateral acupoints: Hegu (LI14), Quchi (LI11), Zusanli (ST36), and Taichong (LR3) (Figure 1). The four acupoints were considered to have BP-lowering effects according to traditional Chinese medicine concepts, and the choice of the above acupoints was supported by previous studies that used TEAS to treat LI4 and LI11 on the forearm or acupuncture at the above acupoints demonstrating a significant BP reduction.24,25,31 Participants in the intervention group were required to have undergone TEAS at LI4 and LI11 on the same arm for 15 min, followed by the same acupoints on the opposite arm for a total of 30 min. Each TEAS treatment lasted a total of 30 min, and participants were asked to alternate the treatment location on alternate days to ensure that they received four TEAS treatments per week for 12 weeks. In addition, participants were asked to take photos to provide feedback to the investigators during the initial treatment to ensure that they had a comprehensive understanding of the TEAS treatment operation. After 12 weeks of treatment, the participants were not required to continue the TEAS intervention. However, we could not determine whether the participants voluntarily continued with the intervention; however, due to the fact that we did not provide any more bespoke self-adhesive electrodes, the participants were unlikely to use the equipment for too long without the electrodes.

2.2 Measures

The primary outcome was the change in mean systolic blood pressure (SBP) measured at baseline and week 12. Other secondary BP outcomes included measures of changes in mean SBP from baseline to 4, 8, 24, and 36 weeks and mean DBP from baseline to 4, 8, 12, 24, and 36 weeks. Additional secondary outcomes measured at weeks 12, 24, and 36 were the proportion of participants developing hypertension (a mean SBP greater than 140 mmHg and/or a mean DBP greater than 90 mmHg), quality of life measured with the 12-item Short Form Health Survey (SF-12), body mass index (BMI) and waist circumference (Supplementary figure).

The process of measuring BP was performed according to a standard protocol recommended by the 2018 Chinese Guidelines for Prevention and Treatment of Hypertension.14 BP was measured with participants in a seated position after 5 min of rest by an assessor using a digital BP monitor (HEM-7136, OMRON Corporation, Kyoto, Japan) with a suitable cuff size in a standardized fashion. Participants were required to avoid exercise, alcohol, cigarettes and coffee/tea for at least 30 min before the BP measurement was performed. The assessor recorded three sequential BP readings at 5-min intervals, and the final BP was calculated by removing the initial reading and calculating the mean from the two remaining readings. Participants recorded adverse events during the study, and feedback was provided to the investigators in a timely manner.

2.3 Sample size

In this pilot study, we aimed to assess the effectiveness and safety of TEAS combined with lifestyle modification for high-normal BP and determine the feasibility of a further large clinical trial. As a feasibility pilot study, our trial was not subject to a formal sample size estimation. The data collected in this trial will allow us to refine our sample size estimates for the primary trial. As a feasibility pilot study, our trial was not subject to a formal sample size estimation. The data collected in this trial will allow us to refine our sample size estimates for the primary trial. We chose 30 participants in each group (which is the most frequently prescribed sample size for pilot studies in the literature32) as a suitable sample size for the comparisons. This was determined to be a sufficiently large sample size to confirm the feasibility of the trial design.

2.4 Statistical analysis

The analysis was performed on an intention-to-treat (ITT) basis by using SPSS 23.0 statistical software (IBM SPSS Statistics, New York,
USA), with a two-sided p-value of <.05 indicating statistical significance. Continuous variables conforming to a normal distribution were compared by using a Student’s t-test, whereas those that were non-normally distributed were tested by using the Mann–Whitney U-test. Differences in proportions and binary variables were compared by using the Chi-square test or Fisher’s exact test. Missing data were imputed by using the last observation carried forward. Even if participants dropped out of the study, we still needed to include them in the statistical analysis according to the predesigned ITT definition. The baseline data were used as the last observation when no follow-up data was available.

3 RESULTS

A total of 97 participants were screened, of whom 60 participants were randomly assigned to the trial (Figure 2). The main reason for exclusion was not meeting the diagnostic criteria of high-normal BP. The disease characteristics of all of the randomized participants at baseline were similar between the two groups (Table 1). After randomization, seven (12%) participants were lost to follow-up (three participants in the intervention group and four participants in the control group; p = 1.0, \( \chi^2 \)-test). The average number of TEAS treatments for each participant in the intervention group was 44.32 ± 6.18 times, which showed that the compliance of the participants was good.

SBP was significantly reduced from 129.38 ± 8.04 at baseline to 124.28 ± 9.62 mmHg (−5.10 ± 5.93 mmHg) at week 12 in the intervention group and reduced from 129.05 ± 9.57 to 127.80 ± 9.54 mmHg (−1.25 ± 8.30 mmHg) in the control group (Table 2, Figure 3). DBP was reduced from 82.25 ± 7.06 to 78.83 ± 7.74 mmHg (−3.42 ± 7.72 mmHg) in the intervention group and from 80.85 ± 7.48 to 79.70 ± 7.01 mmHg (−1.15 ± 5.65 mmHg) in the control group. The mean difference in the change in SBP for the intervention group compared to the control group at week 12 was −3.85 mmHg (−7.58 to −1.12, p = .043); for DBP, the mean difference in the change was −2.27 mmHg (−5.76 to 1.23, p = .199) (Table 2). The mean decreases in SBP and DBP in the intervention group were −5.10 ± 5.93 mmHg (p < .001) and −3.42 ± 7.72 mmHg (p = .022), respectively, compared with the baseline values; however, no changes were observed in the control group (Table 3).

Quality of life, as measured by the SF-12, was not significantly different between each group at the week 12–36 follow-up (Table 4). Similarly, BMI and waist circumference were not significantly different between baseline and follow-up in the intervention group, compared with the control group (Table 4). The proportion of progression to hypertension was not significantly lower in the intervention groups at
TABLE 1  Baseline characteristics

|                          | Intervention group (n = 30) | Control group (n = 30) | p-Value |
|--------------------------|----------------------------|------------------------|---------|
| **Sex, n (%)**           |                            |                        |         |
| Female 20 (66.7)         | 18 (60.0)                  | .789                   |
| Male 10 (33.3)           | 12 (40.0)                  |                        |         |
| **Age, in years**        | 54.13 ± 7.59               | 53.57 ± 9.21           | .796    |
| **BMI, kg/m²**           | 26.00 ± 3.07               | 25.57 ± 3.25           | .597    |
| **Waist circumference (cm)** | 89.57 ± 10.02             | 86.27 ± 12.28          | .259    |
| **Systolic blood pressure, mmHg** | 129.38 ± 8.04         | 129.05 ± 9.57          | .884    |
| **Diastolic blood pressure, mmHg** | 82.25 ± 7.06            | 80.85 ± 7.48           | .459    |
| **12-item short form health survey** |                      |                        |         |
| Physical score           | 49.79 ± 5.83               | 47.99 ± 6.48           | .262    |
| Mental score             | 52.18 ± 7.31               | 52.74 ± 9.04           | .794    |

Note: Values are means (standard deviation) or percentages. Abbreviation: BMI, body mass index.

TABLE 2  Mean systolic blood pressure outcomes (including primary outcome)

| Variable                  | Intervention group (n = 30) | Control group (n = 30) | Difference in mean change (95% CI) | Intervention group versus control group | p-Value |
|---------------------------|----------------------------|------------------------|------------------------------------|----------------------------------------|---------|
| **Systolic blood pressure (mm Hg)** |                        |                        |                                    |                                       |         |
| Baseline                  | 129.38 ± 8.04             | 129.05 ± 9.57          | –                                  | –                                     | –       |
| Week 12                   | 124.28 ± 9.62             | 127.80 ± 9.54          | –3.52 (–7.58 to .12)               | .043                                  |         |
| Week 24                   | 123.58 ± 8.90             | 126.73 ± 8.57          | –3.48 (–7.57 to .61)               | .093                                  |         |
| Week 36                   | 123.32 ± 8.72             | 125.53 ± 9.57          | –2.55 (–7.10 to 2.00)              | .266                                  |         |
| **Diastolic blood pressure (mm Hg)** |                        |                        |                                    |                                       |         |
| Baseline                  | 82.25 ± 7.06              | 80.85 ± 7.48           | –                                  | –                                     | –       |
| Week 12                   | 78.83 ± 7.74              | 79.70 ± 7.01           | –2.27 (–5.76 to 1.23)              | .199                                  |         |
| Week 24                   | 77.98 ± 6.28              | 78.83 ± 7.34           | –2.25 (–6.07 to 1.57)              | .243                                  |         |
| Week 36                   | 78.02 ± 7.03              | 78.32 ± 6.92           | –1.70 (–5.53 to 2.13)              | .378                                  |         |

Note: Values are means (standard deviation). Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index.

FIGURE 3  Mean blood pressure during trial follow-up in the intervention and control groups. Note: Systolic blood pressure (left) and diastolic blood pressure (right). The point estimates are mean blood pressure and error bars represent 95% CIs. *p < .05, mean between-group differences in the changes in blood pressure from baseline.
TABLE 3  Mean difference change relative to baseline

| Variable                  | Intervention group (n = 30) | p-Value   | Control group (n = 30) | p-Value   |
|---------------------------|----------------------------|-----------|------------------------|-----------|
| Systolic blood pressure (mmHg) |                            |           |                        |           |
| Week 12                   | $-5.10 \pm 5.93$           | <.001     | $-1.25 \pm 8.30$       | .416      |
| Week 24                   | $-5.80 \pm 7.98$           | <.001     | $-2.32 \pm 7.84$       | .116      |
| Week 36                   | $-6.07 \pm 8.33$           | <.001     | $-3.52 \pm 9.24$       | .046      |
| Diastolic blood pressure (mmHg) |                            |           |                        |           |
| Week 12                   | $-3.42 \pm 7.72$           | .022      | $-1.15 \pm 5.65$       | .274      |
| Week 24                   | $-4.27 \pm 7.68$           | .005      | $-2.02 \pm 7.09$       | .130      |
| Week 36                   | $-4.23 \pm 8.66$           | .012      | $-2.53 \pm 5.90$       | .026      |

Note: Values are means (SD).

TABLE 4  Secondary outcomes at 12, 24, and 36 weeks

| Variable                                | Intervention group (n = 30) | Control group (n = 30) | Intervention group versus control group (95% CI) | p-Value   |
|-----------------------------------------|-----------------------------|------------------------|-------------------------------------------------|-----------|
| The 12-item Short Form Survey (SF-12)   |                             |                        |                                                 |           |
| Physical score week 12                  | $51.17 \pm 5.25$            | $49.74 \pm 5.63$       | $1.43 (-1.39 to 4.24)$                          | .736      |
| Mental score week 12                    | $52.61 \pm 5.74$            | $53.25 \pm 7.98$       | $-0.64 (-4.23 to 2.96)$                         | .320      |
| Physical score week 24                  | $50.67 \pm 4.03$            | $49.84 \pm 4.90$       | $0.84 (-1.48 to 3.15)$                         | .472      |
| Mental score week 24                    | $53.83 \pm 6.67$            | $53.08 \pm 7.30$       | $0.74 (-2.87 to 4.36)$                         | .683      |
| Physical score week 36                  | $52.84 \pm 4.69$            | $51.72 \pm 4.70$       | $1.12 (-1.31 to 3.55)$                         | .360      |
| Mental score week 36                    | $53.42 \pm 3.81$            | $52.98 \pm 5.43$       | $0.44 (-1.98 to 2.86)$                         | .717      |
| BMI (kg/m²)                             |                             |                        |                                                 |           |
| Week 12                                 | $25.87 \pm 3.26$            | $25.35 \pm 3.20$       | $0.52 (-1.15 to 2.18)$                         | .538      |
| Week 24                                 | $25.28 \pm 2.97$            | $24.96 \pm 3.14$       | $-0.32 (-1.26 to 1.90)$                        | .686      |
| Week 36                                 | $25.25 \pm 2.77$            | $24.88 \pm 3.31$       | $0.36 (-1.21 to 1.94)$                         | .645      |
| Waist circumference (cm)                |                             |                        |                                                 |           |
| Week 12                                 | $88.73 \pm 10.55$           | $85.67 \pm 12.35$      | $3.07 (-2.87 to 9.00)$                         | .305      |
| Week 24                                 | $87.20 \pm 9.84$            | $84.70 \pm 11.80$      | $2.50 (-3.11 to 8.11)$                         | .376      |
| Week 36                                 | $86.87 \pm 9.72$            | $84.17 \pm 11.84$      | $2.70 (-2.90 to 8.30)$                         | .338      |

Note: Values are means (standard deviation).
Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index.

TABLE 5  The proportion of participants achieving hypertension

| Variable                  | Intervention group (n = 30) | Control group (n = 30) | p-Value   |
|---------------------------|----------------------------|------------------------|-----------|
| Week 12, n (%)            | 3 (10.0)                   | 5 (16.7)               | .704      |
| Week 24, n (%)            | 1 (3.3)                    | 2 (6.7)                | 1.0       |
| Week 36, n (%)            | 1 (3.3)                    | 2 (6.7)                | 1.0       |

*aThe proportion of participants achieving hypertension was defined as the proportion of patients with a mean SBP greater than 140 mmHg and/or a mean DBP greater than 90 mmHg.

In the intervention group, 2 (7.7%) participants reported at least one TEAS-related adverse event compared with no participants in the control group. None of the participants withdrew from the study because of an adverse event. All of the adverse events occurred only once and resolved spontaneously. No serious adverse events were reported by any of the participants in either group (Table 6).
Limitations in a single patient was defined as two adverse events. A mean SBP of 130 mmHg at baseline without comorbidities generated a 6-weeks time period caused an 8-mmHg reduction in SBP for patients with mild hypertension, and the effect on SBP reduction lasted for another 6 week after the acupuncture treatment was terminated. In this trial, we found that TEAS combined with lifestyle modification lowered the mean SBP by 5 mmHg and lowered the mean DBP by 3 mmHg. One possible reason for the discrepancies may be the differences in the therapeutic schedule. Another reason could be that patients with higher baseline BP have more capacity for lowering BP. A mean SBP of 130 mmHg at baseline without comorbidities generally represents acceptable control; hence, aiming for even better BP control in this context may have been challenging.

The preliminary results of the BPLTTC trial showed that for patients with different BP stages, each 5-mmHg SBP reduction can reduce the risk of stroke, ischemic heart disease, heart failure and death by 13%, 7%, 14%, and 5%, respectively. A prospective cohort study involving over .5 million adults from 10 areas of China showed that, with normal adults as the reference, adults with high-normal BP had a higher risk of cerebrovascular disease and hemorrhagic stroke, and they were associated with the increased mortality of overall cardiovascular disease and its subtypes. Intensive BP control can reduce the risk of stroke in individuals with increased cardiovascular risk, even in the ranges of high normal and normal BP. In our trial, the target population was BP in the high-normal range because such individuals not only have increased BP but also have an increased prevalence of being overweight and obesity, which places them at greater cardiometabolic risk than people in the general population. Despite this pilot study not having enough power to detect cardiovascular outcomes, our findings still have significant clinical implications and provide support for interventions to improve BP control in individuals with high-normal BP. However, the results of weight and waist circumference evaluations showed that the effect of recommendations for lifestyle modification was not satisfactory. One possible explanation for this phenomenon is that people were under lockdown because of the viral pandemic. In this scenario, they were sheltered at home and in self-isolation to limit the spread of the virus during the COVID-19 pandemic period. This restriction of activities may be a potential cause for the poor effect of lifestyle modification. Although we provided healthy nutrition education and encouragement for physical activity, a targeted diet and weight-loss strategy were not provided. In this study, the extent of BP reduction may not yet be sufficient to affect quality of life, and the sample size was relatively small, which may be insufficient to observe differences in the progression to hypertension.

The main intervention involved transcutaneous electrical stimulation, which solely involves skin-contact stimulation and does not penetrate the skin, similar to acupuncture. We provided information on lifestyle modification for participants via smartphones and social media, which is widely used in community chronic disease management. Due to the pragmatic nature of the study, we integrated these interventions into real-world settings, and a multi-component intervention was conducted via participants’ self-management at home to further reduce the costs of treatment. A more self-determined and flexible time may be a particular advantage. Such an approach represents substantial savings in cost and time to outpatient care, compared with traditional acupuncture. One of the goals of this pilot study was to determine the feasibility of using home-based interventions. To the best of our knowledge, our participants were able to adequately perform the trial intervention at home, and TEAS treatment appeared to be reliably and safely performed. The recruitment and follow-up rates in the study were acceptable, and the desired BP control results were achieved. Hence, the results of this trial support the feasibility of conducting a large randomized trial in the future. A total of 296 patients will be required for an adequately powered future trial, based upon our results.

### 4 Discussion

To the best of our knowledge, this was the first randomized controlled clinical trial to investigate the effectiveness of TEAS combined with lifestyle modification in individuals with high-normal BP. This pilot trial indicated that a home-based multicomponent intervention was effective in reducing SBP. The results indicate that the design is safe and feasible, which justifies the need for a larger trial in the future.

A recent study showed that 18 sessions of electroacupuncture during a 6-weeks time period caused an 8-mmHg reduction in SBP for patients with mild hypertension, and the effect on SBP reduction lasted for another 6 week after the acupuncture treatment was terminated. In this trial, we found that TEAS combined with lifestyle modification lowered the mean SBP by 5 mmHg and lowered the mean DBP by 3 mmHg. One possible reason for the discrepancies may be the differences in the therapeutic schedule. Another reason could be that patients with higher baseline BP have more capacity for lowering BP. A mean SBP of 130 mmHg at baseline without comorbidities generally represents acceptable control; hence, aiming for even better BP control in this context may have been challenging.

The preliminary results of the BPLTTC trial showed that for patients with different BP stages, each 5-mmHg SBP reduction can reduce the risk of stroke, ischemic heart disease, heart failure and death by 13%, 7%, 14%, and 5%, respectively. A prospective cohort study involving over .5 million adults from 10 areas of China showed that, with normal adults as the reference, adults with high-normal BP had a higher risk of cerebrovascular disease and hemorrhagic stroke, and they were associated with the increased mortality of overall cardiovascular disease and its subtypes. Intensive BP control can reduce the risk of stroke in individuals with increased cardiovascular risk, even in the ranges of high normal and normal BP. In our trial, the target population was BP in the high-normal range because such individuals not only have increased BP but also have an increased prevalence of being overweight and obesity, which places them at greater cardiometabolic risk than people in the general population. Despite this pilot study not having enough power to detect cardiovascular outcomes, our findings still have significant clinical implications and provide support for interventions to improve BP control in individuals with high-normal BP. However, the results of weight and waist circumference evaluations showed that the effect of recommendations for lifestyle modification was not satisfactory. One possible explanation for this phenomenon is that people were under lockdown because of the viral pandemic. In this scenario, they were sheltered at home and in self-isolation to limit the spread of the virus during the COVID-19 pandemic period. This restriction of activities may be a potential cause for the poor effect of lifestyle modification. Although we provided healthy nutrition education and encouragement for physical activity, a targeted diet and weight-loss strategy were not provided. In this study, the extent of BP reduction may not yet be sufficient to affect quality of life, and the sample size was relatively small, which may be insufficient to observe differences in the progression to hypertension.

The main intervention involved transcutaneous electrical stimulation, which solely involves skin-contact stimulation and does not penetrate the skin, similar to acupuncture. We provided information on lifestyle modification for participants via smartphones and social media, which is widely used in community chronic disease management. Due to the pragmatic nature of the study, we integrated these interventions into real-world settings, and a multi-component intervention was conducted via participants’ self-management at home to further reduce the costs of treatment. A more self-determined and flexible time may be a particular advantage. Such an approach represents substantial savings in cost and time to outpatient care, compared with traditional acupuncture. One of the goals of this pilot study was to determine the feasibility of using home-based interventions. To the best of our knowledge, our participants were able to adequately perform the trial intervention at home, and TEAS treatment appeared to be reliably and safely performed. The recruitment and follow-up rates in the study were acceptable, and the desired BP control results were achieved. Hence, the results of this trial support the feasibility of conducting a large randomized trial in the future. A total of 296 patients will be required for an adequately powered future trial, based upon our results.

#### 4.1 Limitations

The present study had some limitations to be considered. For example, this study was performed in an unblinded fashion. We did not employ a sham control because it was difficult to blind the participants so that they could tell whether the instrument was on. However, due to the automatic mode of the sphygmomanometer that was used, it is unlikely that this objective outcome was influenced by the unblinded nature of the intervention. Second, the optimal frequency of electrical stimulation of TEAS could not be elucidated in this study. Third, although we

| Table 6: Adverse events |
|-------------------------|
|                        |
| Overall                 |
| 2                      |
| Control group (n = 30)  |
| 0                      |
| Severe adverse events  |
| 0                      |
| Fatigue                |
| 1                      |
| Muscular soreness      |
| 1                      |

*Adverse events were analyzed in all participants. Adverse events were counted by frequency in patients. For example, an adverse event with two occurrences in a single patient was defined as two adverse events.
CONCLUSIONS

In this prospective, randomized controlled study, lifestyle modification combined with home-based TEAS modestly decreased BP at week 12 in a population of adults with high-normal BP, compared to the sole use of lifestyle modification. Although the clinical significance of these findings remains to be further confirmed, our trial shows the potential of a pragmatic, nonpharmaceutical, home-based intervention for BP control, especially under lockdown during the COVID-19 pandemic period. The results of this trial support the feasibility of conducting a larger randomized trial in the future.

ACKNOWLEDGMENTS

The authors acknowledge the support of the Heyi community health service centers (formerly Nanyuan community health service centers) in Beijing, China. The authors especially thank Professor Myeong Soo Lee and Professor Marc Fisher for their review of the content and language of the manuscript. The study was funded by the National Key R&D Program of China (2019YFC1712102) and the Fundamental Research Funds for the Central Universities (No. 2019-JYB-XJSJJ-31). The funding plays no role in the study design; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

Concept and design: Yu Wang, Zhong-Xue Tian, Li-Qiong Wang, Jing-Wen Yang, Jian-Feng Tu, Guang-Xia Shi and Cun-Zhi Liu; Acquisition of data: Zhong-Xue Tian, Jun-Hong Liu, You-Sheng Qi and Jian-Feng Tu; Statistical analysis: Yu Wang, Shi-Yan Yan; Interpretation of results: Yu Wang, Jing-Wen Yang, Guang-Xia Shi, Li-Qiong Wang and Cun-Zhi Liu; Drafting of the manuscript: Yu Wang and Li-Qiong Wang; Critical revision of the manuscript for important intellectual content: Yu Wang, Li-Qiong Wang, Jing-Wen Yang, Jian-Feng Tu, Guang-Xia Shi, Shi-Yan Yan and Cun-Zhi Liu; Administrative: Jun-Hong Liu and You-Sheng Qi.

AUTHOR STATEMENT

Yu Wang: concept and design; statistical analysis; interpretation of results; drafting of the manuscript; critical revision of the manuscript for important intellectual content. Jing-Wen Yang: concept and design; acquisition of data; administrative. You-Sheng Qi: acquisition of data; administrative. Jian-Feng Tu: concept and design; acquisition of data; critical revision of the manuscript for important intellectual content. Jun-Hong Liu: acquisition of data; administrative. You-Sheng Qi: acquisition of data; administrative. Jian-Feng Tu: concept and design; acquisition of data; critical revision of the manuscript for important intellectual content. Shi-Yan Yan: statistical analysis; critical revision of the manuscript for important intellectual content. Li-Qiong Wang: concept and design; interpretation of results; drafting of the manuscript; critical revision of the manuscript for important intellectual content. Cun-Zhi Liu: concept and design; interpretation of results; critical revision of the manuscript for important intellectual content.

ORCID

Li-Qiong Wang MD, PhD  https://orcid.org/0000-0003-1222-7715

REFERENCES

1. Geldsetzer P, Manne-Goehler J, Marcus ME, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet. 2019;394(10199):652-662.
2. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386(9995):801-812.
3. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-2223.
4. He J, Gu D, Chen J, et al. Premature deaths attributable to blood pressure in China: a prospective cohort study. Lancet. 2009;374(9703):1765-1772.
5. Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145-1158.
6. Egan BM, Stevens-Fabry S. Prehypertension–prevalence, health risks, and management strategies. Nat Rev Cardiol. 2015;12(5):289-300.
7. Kanegae H, Oikawa T, Kario K. Should pre-hypertension be treated. Curr Hypertens Rep. 2017;19(11):91.
8. Jimenez-Corona A, Lopez-Ridaura R, Stern MP, Gonzalez-Villalpando C. Risk of progression to hypertension in a low-income Mexican population with prehypertension and normal blood pressure. Am J Hypertens. 2007;20(9):929-936.
9. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med. 2013;11:177.
10. Shen T, Xing G, Zhu J, et al. Effects of 12-week supplementation of a polyherbal formulation in old adults with prehypertension/hypertension: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med. 2019;2019:7056872.
11. Egan BM, Stevens-Fabry S. The importance of masked hypertension in adults with prehypertension. Nat Rev Cardiol. 2015;12(8):497.
12. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens. 2009;27(5):923-934.
WANG ET AL.

13. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012(8):CD006742.

14. Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16(3):182-241.

15. Janke EA, Richardson C, Schneider KL. Society of Behavioral Medicine Executive Committee. Beyond pharmacotherapy: lifestyle counseling guidance needed for hypertension. Ann Intern Med. 2019;170(3):195-196.

16. Liang Y, Bao G, Gong L, et al. Evaluating the analgesic effect and advantage of transcutaneous electrical acupoint stimulation combined with opioid drugs for moderate to severe cancer-related pain: a study protocol for a randomized controlled trial. Trials. 2019;20(1):40.

17. Zhang B, Xu JF, Wang L, et al. Needleless transcutaneous electrical acupoint stimulation: a pilot study evaluating improvement in post-operative recovery. Am J Gastroenterol. 2018;113(7):1026-1035.

18. Liu S, Peng S, Hou X, Ke M, Chen JD. Transcutaneous electroacupuncture improves dyspeptic symptoms and increases high frequency heart rate variability in patients with functional dyspepsia. Neurogastroenterol Motil. 2008;20(11):1204-1211.

19. Zhang N, Song G, Chen J, et al. Ameliorating effects and autonomic mechanisms of needle-less transcutaneous electrical stimulation at ST36 on stress-induced impairment in gastric slow waves. J Gastroenterol Hepatol. 2015;30(11):1574-1581.

20. Zhang B, Zhu K, Hu P, Xu F, Zhu L, Chen J. Needleless transcutaneous neuromodulation accelerates postoperative recovery mediated via autonomic and immuno-cytokine mechanisms in patients with cholecystolithiasis. Neuromodulation. 2019;22(5):546-554.

21. Yang NN, Yang JW, Ye Y, et al. Electroacupuncture ameliorates intestinal inflammation by activating α7nAChR-mediated JAK2/STAT3 signaling pathway in postoperative ileus. Theranostics. 2021;11(9):4078-4089.

22. da Silva ML, Chiappa GR, da Silva VM, et al. Effect of transcutaneous electrical nerve stimulation on peripheral to central blood pressure ratio in healthy subjects. Clin Physiol Funct Imaging. 2016;36(4):293-297.

23. Silverdal J, Mouritzis G, Stener-Victorin E, Mannheimer C, Manhem K. Antihypertensive effect of low-frequency transcutaneous electrical nerve stimulation (TENS) in comparison with drug treatment. Blood Press. 2012;21(5):306-310.

24. Jacobsson F, Himmelmann A, Bergbrant A, Svensson A, Mannheimer C. The effect of transcutaneous electric nerve stimulation in patients with therapy-resistant hypertension. J Hum Hypertens. 2000;14(12):795-798.

25. Zhang J, Ng D, Sau A. Effects of electrical stimulation of acupuncture points on blood pressure. J Chiropr Med. 2009;8(1):9-14.

26. Tu JF, Wang LQ, Liu JH, et al. Home-based transcutaneous electrical acupoint stimulation for hypertension: a randomized controlled pilot trial. Hypertens Res. 2021;44(10):1300-1306.

27. Chen WT, Wei JF, Wang L, et al. Effects of perioperative transcutaneous electrical acupoint stimulation on monocyteic HLA-DR expression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass: study protocol for a double-blind randomized controlled trial. Trials. 2019;20(1):789.

28. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c669.

29. Wang Y, Shi GX, Tian ZX, et al. Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial. Trials. 2021;22(1):140.

30. Li X, Li T, Chen J, et al. A wechat-based self-management intervention for community middle-aged and elderly adults with hypertension in Guangzhou, China: a cluster-randomized controlled trial. Int J Environ Res Public Health. 2019;16(21):4058.

31. Zheng H, Li J, Li Y, et al. Acupuncture for patients with mild hypertension: a randomized controlled trial. J Clin Hypertens (Greenwich). 2019;21(3):412-420.

32. Wang Y, Wang LQ, Yang JW, et al. (Application and reflection on pilot study in acupuncture clinical research). Zhongguo Zhen Jiu. 2021;41(3):325-329.

33. Bobrow K, Farmer AJ, Springer D, et al. Mobile phone text messages to support treatment adherence in adults with high blood pressure (SMS-text adherence support [StAR]): a single-blind, randomized trial. Circulation. 2016;133(6):592-600.

34. Jia X, Hussain A, et al. Highlights from studies in cardiovascular disease prevention presented at the digital 2020 European Society of Cardiology Congress: prevention is alive and well. Curr Atheroscler Rep. 2020;22(12):72.

35. Guo J, Lv J, Guo Y, et al. Association between blood pressure categories and cardiovascular disease mortality in China. PLoS One. 2021;16(7):e0255373.

36. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35(11):2150-2160.

37. Hansen TW, Staessen JA, Zhang H, et al. Cardiovascular outcome in relation to progression to hypertension in the Copenhagen MONICA cohort. Am J Hypertens. 2007;20(5):483-491.

38. Dorje T, Zhao G, Tso K, et al. Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. 2019;1(7):e363-e374.

39. He C, Wu S, Zhao Y, et al. Social media-promoted weight loss among an occupational population: cohort study using a wechat mobile phone app-based campaign. J Med Internet Res. 2017;19(10):e357.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Wang Y, Yang J-W, Liu J-H, et al. Home-based transcutaneous electrical acupoint stimulation for high-normal blood pressure: A randomized controlled trial. J Clin Hypertens. 2022;24:984–992. https://doi.org/10.1111/jch.14496